Komori
Sankyo (6417) · FactR&D expenses slightly down, activity status unchanged

Large-scale R&D organisation and brand-based product launches

First written in FY2016. 13 of 33 entries say "Restated". Latest entry: FY2027-H1.

33entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2016 – FY2027-H12016: 220162017: 320172018: 420182019: 420192020: 220202021: 420212022: 420222023: 420232024: 320242025: 120252026: 22026
Same theme, other companies
Scale and trends in R&D personnel and spendingA theme 4 companies write about · 1 as a headwind · 1 as a tailwind

2 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1R&D expenses slightly down, activity status unchangedAnnual report

    「Total R&D expenses for the current interim consolidated accounting period were ¥10.0 billion. There were no material changes in the status of the Group's R&D activities during the current interim consolidated accounting period.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses decreased slightly from approximately ¥10.27 billion in the same period of the previous year to approximately ¥10.06 billion.
  2. FY2026Expanded R&D scale; continued product launchesAnnual report

    「The number of staff engaged in research and development was 280 at the end of the current consolidated fiscal year, and total research and development expenses were ¥21.5 billion.」

    R&D staff increased from 267 to 280, and R&D expenses increased from ¥15.2 billion to ¥21.5 billion. Product launches also continued, with 9 pachinko titles and 4 pachislot titles.
  3. FY2026-H1Higher R&D spending; activities unchangedAnnual report

    「Total R&D expenses for the current interim consolidated accounting period were ¥10.2 billion. There were no material changes in the status of the Group's R&D activities during the current interim consolidated accounting period.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses increased from approximately ¥8.3 billion in the same period of the previous year to ¥10.2 billion.
  4. FY2025-H1Higher R&D spending; activities unchangedAnnual report

    「Total R&D expenses for the current interim consolidated accounting period were ¥8.3 billion. There were no material changes in the status of the Group's R&D activities during the current interim consolidated accounting period.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses increased from approximately ¥7.1 billion in the same period of the previous year to ¥8.3 billion.
  5. FY2024Increased R&D expenses; slight decrease in staff; continued product launchesAnnual report

    「The number of staff engaged in research and development was 267 at the end of the current consolidated fiscal year, and total research and development expenses were ¥15.2 billion.」

    R&D staff edged down from 270 in the previous fiscal year to 267, while R&D expenses increased from ¥14.2 billion to ¥15.2 billion, and the company continued launching 10 pachinko titles and 5 pachislot titles.
  6. FY2024-Q3Higher R&D spending; activities unchangedAnnual report

    「The total amount of research and development expenses for the cumulative third quarter of the current consolidated fiscal year was ¥11.1 billion. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses increased from ¥10.2 billion in the same period of the previous year to ¥11.1 billion.
  7. FY2024-Q2Higher R&D spending; activities unchangedAnnual report

    「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥7.1 billion. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses increased from ¥6.4 billion in the same period of the previous year to ¥7.1 billion.
  8. FY2024-Q1Higher R&D spending; activities unchangedAnnual report

    「The total amount of research and development expenses for the cumulative first quarter of the current consolidated fiscal year was ¥3.5 billion. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses increased from ¥2.5 billion in the same quarter of the previous year to ¥3.5 billion.
  9. FY2023Fewer R&D personnel and higher costsAnnual report

    「The Group's R&D activities are currently conducted by our Product Division and the development departments of each subsidiary. As of the end of the current consolidated fiscal year, R&D staff totaled 270, and total R&D expenses were ¥14.2 billion.」

    R&D staff decreased from 291 in the previous fiscal year to 270, while R&D expenses increased from ¥11.9 billion to ¥14.2 billion. Product launches continued, with 10 pachinko titles and 3 pachislot titles.
  10. FY2023-Q3Higher R&D spending; activities unchangedAnnual report

    「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥10.2 billion. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses increased from ¥8.3 billion in the same period of the previous year to ¥10.2 billion.
  11. FY2023-Q2Higher R&D spending; activities unchangedAnnual report

    「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥6.4 billion. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses increased from ¥5.647 billion in the same period of the previous year to ¥6.4 billion.
  12. FY2023-Q1Higher R&D spending; activities unchangedAnnual report

    「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥2.9 billion. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses increased from ¥2.5 billion in the same period of the previous year to ¥2.9 billion.
  13. FY2022Reduced R&D staff and expenses; continued product launchesAnnual report

    「The Group's R&D activities are currently conducted by our Product Division and the development departments of each subsidiary. As of the end of the current consolidated fiscal year, R&D staff totaled 291, and total R&D expenses were ¥11.9 billion.」

    R&D staff decreased from 298 to 291, and R&D expenses decreased from ¥12.1 billion to ¥11.9 billion, while product launches continued, with 7 pachinko titles and 3 pachislot titles.
  14. FY2022-Q3R&D expenses slightly down, activity status unchangedAnnual report

    「The total amount of research and development expenses for the cumulative third quarter of the current consolidated fiscal year was ¥8.3 billion. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses edged down from ¥8.7 billion in the cumulative same quarter of the previous year to ¥8.3 billion.
  15. FY2022-Q2R&D expenses slightly down, activity status unchangedAnnual report

    「The total amount of research and development expenses for the cumulative second quarter of the current consolidated fiscal year was ¥5.6 billion. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses decreased from ¥5.9 billion in the same period of the previous year to ¥5.6 billion.
  16. FY2022-Q1Reduced R&D expenses; unchanged activity statusAnnual report

    「The total amount of research and development expenses for the cumulative first quarter of the current consolidated fiscal year was ¥2.5 billion. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenses decreased from ¥3.5 billion in the same period of the previous year to ¥2.5 billion.
  17. FY2021Increased R&D staff; reduced expensesAnnual report

    「The number of staff engaged in research and development was 298 at the end of the current consolidated fiscal year, and total research and development expenses were ¥12.1 billion.」

    R&D staff increased from 294 in the previous fiscal year to 298, while R&D expenses decreased from ¥14.6 billion to ¥12.1 billion. Product launches continued, with 9 pachinko titles and 2 pachislot titles.
  18. FY2021-Q3RestatedAnnual report

    「The total amount of research and development expenses for the cumulative third quarter of the current consolidated fiscal year was ¥8.7 billion. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥8.7 billion and reaffirmed that there were no material changes in the status of R&D activities.
  19. FY2021-Q2RestatedAnnual report

    「The total amount of research and development expenses for the cumulative second quarter of the current consolidated fiscal year was ¥5.9 billion. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥5.9 billion and explained that there were no material changes in the status of R&D activities.
  20. FY2020-Q3RestatedAnnual report

    「The total amount of research and development expenses for the cumulative third quarter of the current consolidated fiscal year was ¥10.5 billion. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」

    R&D expenses for the cumulative third quarter were ¥10.5 billion, and the company explained that there were no material changes in the status of R&D activities.
  21. FY2020-Q2RestatedAnnual report

    「The total amount of research and development expenses for the cumulative second quarter of the current consolidated fiscal year was ¥6.9 billion. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥6.9 billion and explained that there were no material changes in the status of R&D activities.
  22. FY2020-Q1RestatedAnnual report

    「The total amount of research and development expenses for the cumulative first quarter of the current consolidated fiscal year was ¥3.5 billion. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥3.5 billion and explained that there were no material changes in the status of R&D activities.
  23. FY2019Reduced R&D scale; continued product launchesAnnual report

    「The number of staff engaged in research and development was 294 at the end of the current consolidated fiscal year, and total research and development expenses were ¥14.6 billion.」

    R&D staff totaled 294, and R&D expenses were ¥14.6 billion, representing a reduction in scale from the previous fiscal year's 316 staff and ¥17.4 billion, while 12 pachinko titles and 5 pachislot titles were sold.
  24. FY2019-Q3RestatedAnnual report

    「The total amount of research and development expenses for the cumulative third quarter of the current consolidated fiscal year was ¥11.1 billion. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥11.1 billion and explained that there were no material changes in the status of R&D activities.
  25. FY2019-Q2RestatedAnnual report

    「The total amount of research and development expenses for the cumulative second quarter of the current consolidated fiscal year was ¥7.4 billion. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」

    R&D expenses for the cumulative second quarter were ¥7.4 billion, and the company explained that there were no material changes in the status of R&D activities.
  26. FY2019-Q1RestatedAnnual report

    「The total amount of research and development expenses for the cumulative first quarter of the current consolidated fiscal year was ¥3.8 billion. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥3.8 billion and explained that there were no material changes in the status of R&D activities.
  27. FY2018Reduced R&D scale; continued product launchesAnnual report

    「The number of staff engaged in research and development was 316 at the end of the current consolidated fiscal year, and total research and development expenses were ¥17.4 billion.」

    R&D staff totaled 316, and R&D expenses were ¥17.4 billion, representing a reduction in scale from the 331 staff and ¥21.9 billion reported for the previous fiscal year, while 15 pachinko titles and 6 pachislot titles were sold.
  28. FY2018-Q3RestatedAnnual report

    「The total amount of research and development expenses for the cumulative third quarter of the current consolidated fiscal year was ¥14.2 billion. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥14.2 billion and explained that there were no material changes in the status of R&D activities.
  29. FY2018-Q2RestatedAnnual report

    「The total amount of research and development expenses for the cumulative second quarter of the current consolidated fiscal year was ¥9.7 billion. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥9.7 billion and explained that there were no material changes in the status of R&D activities.
  30. FY2018-Q1RestatedAnnual report

    「The total amount of research and development expenses for the cumulative first quarter of the current consolidated fiscal year was ¥4.7 billion. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」

    Recorded R&D expenses of ¥4.7 billion and explained that there were no material changes in the status of R&D activities.
  31. FY2017-Q3RestatedAnnual report

    「The total amount of research and development expenses for the cumulative third quarter of the current consolidated fiscal year was ¥14.9 billion. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」

    The company recorded ¥14.9 billion in R&D expenses and stated that there had been no material changes in its R&D activities.
  32. FY2017-Q2RestatedAnnual report

    「The total amount of research and development expenses for the cumulative second quarter of the current consolidated fiscal year was ¥10.3 billion. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」

    The company recorded ¥10.3 billion in R&D expenses and stated that there had been no material changes in its R&D activities.
  33. FY2016First statedAnnual report

    「As of the end of the fiscal year, 331 staff were engaged in research and development, and total R&D expenditure was ¥21.9 billion.」

    The company recorded 331 R&D staff and ¥21.9 billion in R&D expenses, and sold 14 pachinko titles and 6 pachislot titles.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sankyo yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.